ID 110869
Author
Nishimura, Naoki Division of Pulmonary Medicine, St. Luke’s International Hospital
Sugiura, Rika Division of Pulmonary Medicine, St. Luke’s International Hospital
Ueda, Hirotaka Division of Pulmonary Medicine, St. Luke’s International Hospital
Ono, Hiroshi Division of Pulmonary Medicine, St. Luke’s International Hospital
Horinouchi, Hidehito Division of Pulmonary Medicine, St. Luke’s International Hospital
Uchiyama, Noboru Division of Pulmonary Medicine, St. Luke’s International Hospital
Chohnabayashi, Naohiko Division of Pulmonary Medicine, St. Luke’s International Hospital
Keywords
non-small cell lung cancer
gemcitabine
UFT
uracil-tegafur
second-line chemotherapy
Content Type
Journal Article
Description
Gemcitabine plus UFT combination chemotherapy are highly effective and less toxic in the first line setting in patients with non-small cell lung cancer (NSCLC). The purpose of the study is to confirm the feasibility of this regimen as secondor third-line therapy in NSCLC. Methods : Fifteen patients with performance status of 0-1 were enrolled. UFT (tegafur 250 mg/m2/day) was administered orally twice a day from days 1-14, and gemcitabine of 900 mg/m2 was administered intravenously on days 8 and 15 every three weeks on an outpatient setting. The treatment was repeated for at least 3 cycles and continued unless the disease progressed. Results : The response rate and the disease control rate were 6.7% and 66.7%, respectively. Grade 3-4 toxicities included neutropenia in one patient and elevation of transaminases in one patient. The mean relative dose intensity of gemcitabine and UFT were 0.93 and 0.97, respectively. Conclusion : High disease control rate and less toxicity suggested the potential of gemcitabine and UFT combination chemotherapy as second- or third-line therapy in NSCLC.
Journal Title
The journal of medical investigation : JMI
ISSN
13431420
NCID
AA11166929
Volume
55
Issue
3-4
Start Page
260
End Page
266
Sort Key
260
Published Date
2008-08
FullText File
language
eng
TextVersion
Publisher